401 related articles for article (PubMed ID: 26977847)
1. The evolving role of immunotherapy in prostate cancer.
Cordes LM; Gulley JL; Madan RA
Curr Opin Oncol; 2016 May; 28(3):232-40. PubMed ID: 26977847
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
Laccetti AL; Subudhi SK
Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923
[TBL] [Abstract][Full Text] [Related]
3. Understanding the tumor-immune microenvironment in prostate cancer.
Dong L; Myers KV; Pienta KJ
Curr Opin Oncol; 2021 May; 33(3):231-237. PubMed ID: 33606403
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor.
Lou DY; Fong L
Urol Oncol; 2016 Apr; 34(4):182-92. PubMed ID: 24495446
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.
Podrazil M; Horvath R; Becht E; Rozkova D; Bilkova P; Sochorova K; Hromadkova H; Kayserova J; Vavrova K; Lastovicka J; Vrabcova P; Kubackova K; Gasova Z; Jarolim L; Babjuk M; Spisek R; Bartunkova J; Fucikova J
Oncotarget; 2015 Jul; 6(20):18192-205. PubMed ID: 26078335
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.
Singh BH; Gulley JL
Asian J Androl; 2014; 16(3):364-71. PubMed ID: 24435055
[TBL] [Abstract][Full Text] [Related]
7. Combining immunotherapies for the treatment of prostate cancer.
Redman JM; Gulley JL; Madan RA
Urol Oncol; 2017 Dec; 35(12):694-700. PubMed ID: 29146441
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications.
Gulley JL; Madan RA; Heery CR
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714490
[TBL] [Abstract][Full Text] [Related]
9. Current role of immunotherapy for the treatment of prostate cancer.
Porfyris O; Kalomoiris P
J BUON; 2013; 18(4):809-17. PubMed ID: 24344002
[TBL] [Abstract][Full Text] [Related]
10. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
[TBL] [Abstract][Full Text] [Related]
11. [Current status and prospects of immunotherapy for castration-resistant prostate cancer].
Yatsuda J; Eto M
Nihon Rinsho; 2014 Dec; 72(12):2174-8. PubMed ID: 25518354
[TBL] [Abstract][Full Text] [Related]
12. PROSTVAC® targeted immunotherapy candidate for prostate cancer.
Shore ND
Immunotherapy; 2014; 6(3):235-47. PubMed ID: 24762070
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms.
Quinn DI; Shore ND; Egawa S; Gerritsen WR; Fizazi K
Urol Oncol; 2015 May; 33(5):245-60. PubMed ID: 25575714
[TBL] [Abstract][Full Text] [Related]
14. The evolving landscape of immunotherapy in advanced prostate cancer.
Patel VG; Oh WK
Immunotherapy; 2019 Jul; 11(10):903-912. PubMed ID: 31161846
[TBL] [Abstract][Full Text] [Related]
15. Revisiting Immunotherapy: A Focus on Prostate Cancer.
Cha HR; Lee JH; Ponnazhagan S
Cancer Res; 2020 Apr; 80(8):1615-1623. PubMed ID: 32066566
[TBL] [Abstract][Full Text] [Related]
16. Identification of targets for prostate cancer immunotherapy.
Papanicolau-Sengos A; Yang Y; Pabla S; Lenzo FL; Kato S; Kurzrock R; DePietro P; Nesline M; Conroy J; Glenn S; Chatta G; Morrison C
Prostate; 2019 Apr; 79(5):498-505. PubMed ID: 30614027
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic vaccines is a novel approach in castration-resistant prostate cancer treatment].
Djurhuus SS; Brasso K; Berg KD; Iversen P; Røder MA
Ugeskr Laeger; 2015 May; 177(20):. PubMed ID: 25967247
[TBL] [Abstract][Full Text] [Related]
18. Development of PROSTVAC immunotherapy in prostate cancer.
Singh P; Pal SK; Alex A; Agarwal N
Future Oncol; 2015; 11(15):2137-48. PubMed ID: 26235179
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in prostate cancer: challenges and opportunities.
Noguchi M; Koga N; Moriya F; Itoh K
Immunotherapy; 2016; 8(1):69-77. PubMed ID: 26642100
[TBL] [Abstract][Full Text] [Related]
20. Biological and therapeutic advances in the pursuit of effective immunotherapy for prostate cancer.
Hamid AA; Choudhury AD
Curr Opin Urol; 2020 Jan; 30(1):30-35. PubMed ID: 31609776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]